Sartorius/€SRT3

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Sartorius

Sartorius AG, trading under the ticker symbol SRT3, is a global provider of laboratory and bioprocess technologies, offering products and services that cater to the needs of the biopharmaceutical and research industries. Founded in 1870 and headquartered in Göttingen, Germany, the company specializes in filtration, fermentation, fluid management, and laboratory products, supporting clients ranging from research facilities to large-scale biopharmaceutical manufacturers. Operating internationally, Sartorius is crucial in enabling the development and production of biotech medications and vaccines, solidifying its role as a crucial player in the life sciences and biotechnology sectors.

Ticker

€SRT3

Primary listing

XETRA

Industry

Life Sciences Tools and Services

Employees

13,685

Sartorius Metrics

BasicAdvanced
€12B
-
-
1.24
€0.74
0.38%

What the Analysts think about Sartorius

Analyst ratings (Buy, Hold, Sell) for Sartorius stock.

Bulls say / Bears say

Sartorius AG achieved a 6.5% increase in Group sales revenue in Q1 2025, with the Bioprocess Solutions division experiencing nearly 10% growth, indicating strong demand for consumables. (webdisclosure.com)
The company's underlying EBITDA rose by 12.2% to €263 million in Q1 2025, with the margin improving to 29.8%, reflecting enhanced operational efficiency. (webdisclosure.com)
Sartorius has set a medium-term target to achieve an underlying EBITDA margin of around 34% by 2028, indicating confidence in sustained profitability growth. (sartorius.com)
In H1 2024, Sartorius reported a 2.2% decrease in sales revenue, with the Lab Products & Services division facing challenges due to the Chinese market, highlighting regional vulnerabilities. (finanzwire.com)
The company adjusted its full-year 2024 guidance to a more cautious stance, citing persistent market volatility and a reluctance from customers to place new orders. (finanzwire.com)
Sartorius's debt-to-equity ratio stands at 117.8%, indicating a high level of leverage that could pose financial risks if not managed effectively. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

Sartorius Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sartorius Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SRT3

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs